Literature DB >> 20672998

Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Jessica S Thomas1, Nedra Lacour, Pamela A Kozlowski, Steve Nelson, Gregory J Bagby, Angela M Amedee.   

Abstract

Human immunodeficiency virus (HIV) infections are rarely acquired via an oral route in adults. Previous studies have shown that human whole saliva inhibits HIV infection in vitro, and multiple factors present in human saliva have been shown to contribute to this antiviral activity. Despite the widespread use of simian immunodeficiency virus (SIV)-infected rhesus macaques as models for HIV pathogenesis and transmission, few studies have monitored SIV in the oral cavity of infected rhesus macaques and evaluated the viral inhibitory capacity of macaque saliva. Utilizing a cohort of rhesus macaques infected with SIV(Mac251), we monitored virus levels and genotypic diversity in the saliva throughout the course of the disease; findings were similar to previous observations in HIV-infected humans. An in vitro infectivity assay was utilized to measure inhibition of HIV/SIV infection by normal human and rhesus macaque whole saliva. Both human and macaque saliva were capable of inhibiting HIV and SIV infection. The inhibitory capacity of saliva samples collected from a cohort of animals postinfection with SIV increased over the course of disease, coincident with the development of SIV-specific antibodies in the saliva. These findings suggest that both innate and adaptive factors contribute to inhibition of SIV by whole macaque saliva. This work also demonstrates that SIV-infected rhesus macaques provide a relevant model to examine the innate and adaptive immune responses that inhibit HIV/SIV in the oral cavity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20672998      PMCID: PMC2957632          DOI: 10.1089/aid.2009.0235

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Limits on oral transmission of HIV-1.

Authors:  M S Cohen; D C Shugars; S A Fiscus
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

2.  Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection.

Authors:  Stephanie A Freel; Susan A Fiscus; Christopher D Pilcher; Prema Menezes; Julieta Giner; Ericka Patrick; Jeffrey L Lennox; Charles B Hicks; Joseph J Eron; Diane C Shugars
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

3.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Authors:  K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson
Journal:  Virology       Date:  2001-11-10       Impact factor: 3.616

4.  Use of infectious molecular clones of simian immunodeficiency virus for pathogenesis studies.

Authors:  H W Kestler; Y N Naidu; T Kodama; N W King; M D Daniel; Y Li; R C Desrosiers
Journal:  J Med Primatol       Date:  1989       Impact factor: 0.667

5.  Components of saliva inactivate human immunodeficiency virus.

Authors:  P N Fultz
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses.

Authors:  S A Freel; J M Williams; J A Nelson; L L Patton; S A Fiscus; R Swanstrom; D C Shugars
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions.

Authors:  S W Wang; P A Kozlowski; G Schmelz; K Manson; M S Wyand; R Glickman; D Montefiori; J D Lifson; R P Johnson; M R Neutra; A Aldovini
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva.

Authors:  D C Shugars; G D Slade; L L Patton; S A Fiscus
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2000-04

Review 9.  Oral mucosal immunity and HIV infection: current status.

Authors:  S J Challacombe; S P Sweet
Journal:  Oral Dis       Date:  2002       Impact factor: 3.511

10.  Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model.

Authors:  James B Whitney; Corinne Luedemann; Saran Bao; Ayako Miura; Srinivas S Rao; John R Mascola; Norman L Letvin
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

View more
  4 in total

1.  Effects of alcohol consumption on antigen-specific cellular and humoral immune responses to SIV in rhesus macaques.

Authors:  Bapi Pahar; Angela M Amedee; Jessica Thomas; Jason P Dufour; Ping Zhang; Steve Nelson; Ronald S Veazey; Gregory J Bagby
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

2.  Impact of mucosal inflammation on oral simian immunodeficiency virus transmission.

Authors:  Luis D Giavedoni; Hui-Ling Chen; Vida L Hodara; Lianrui Chu; Laura M Parodi; Lisa M Smith; Valerie Sexton; David Cappelli; Donald L Sodora
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

3.  Optimization of a Novel Non-invasive Oral Sampling Technique for Zoonotic Pathogen Surveillance in Nonhuman Primates.

Authors:  Tierra Smiley Evans; Peter A Barry; Kirsten V Gilardi; Tracey Goldstein; Jesse D Deere; Joseph Fike; JoAnn Yee; Benard J Ssebide; Dibesh Karmacharya; Michael R Cranfield; David Wolking; Brett Smith; Jonna A K Mazet; Christine K Johnson
Journal:  PLoS Negl Trop Dis       Date:  2015-06-05

Review 4.  Challenges in mucosal HIV vaccine development: lessons from non-human primate models.

Authors:  Iskra Tuero; Marjorie Robert-Guroff
Journal:  Viruses       Date:  2014-08-15       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.